Q

Quotient Sciences | Nottingham

Research site
(Unclaimed)
Location
Mere Way Ruddington Fields, Nottingham, Nottingham, England
Site insights

Top conditions

Fibrosis (3 trials)

Hemorrhage (2 trials)

Cystic Fibrosis (2 trials)

Parkinson Disease (2 trials)

Mycoses (1 trial)

Top treatments

anle138b
BOS172767
FDL169
Relugolix
BMS-986165
NM-101
DNDI-0690
Cloxacillin
Trimethoprim
14C-NW-3509

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 57
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

This is a single center, double-blind, randomized, placebo-controlled, single ascending subcutaneous dose study in lean to overweight or obese but ot...

Enrolling
Overweight
Healthy Volunteers
Drug: GUB014295-PLACEBO
Drug: GUB014295

The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral...

Enrolling
Healthy
Drug: BI 1015550
Drug: Moxifloxacin

The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in health...

Enrolling
Healthy Volunteers
Drug: Afimetoran
Drug: Famotidine

This is a Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Follow...

Enrolling
Healthy
Cough
Drug: BLU-5937 ER
Drug: BLU-5937 IR

A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subject...

Enrolling
Male Contraception
Drug: YCT-529
Drug: YCT-529 Placebo

This is a Phase I, double-blind, randomised, two-part, single-ascending dose (Part 1) and multiple-ascending dose (Part 2) study of NM-101 in healthy...

Not yet enrolling
Parkinson Disease
Drug: NM-101
Drug: Placebo

This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and met...

Active, not recruiting
NASH With Fibrosis
Drug: [14C]-rencofilstat 225mg

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems